Scope & Claims of US Patent 11,103,495 (Racemic Methylphenidate Chewable Tablet with Barrier-Coated Ion-Exchange Complexes)
US 11,103,495 claims a specific extended-release (ER) formulation architecture for racemic methylphenidate in a chewable tablet that uses (i) a barrier-coated ion-exchange resin complex to generate sustained release and (ii) defined immediate-release (IR) racemic methylphenidate components for early exposure. The independent claim set is tightly constrained to a uniform solid dispersion, a barrier coating that is explicitly water-insoluble, water-permeable, pH-independent, and non-enteric, plus specific compositional ranges (barrier coating wt%, plasticizer wt%, and split of sustained vs immediate methylphenidate fractions). Claim 1 is directed to an ER tablet with one IR component releasing in under ~30 minutes; claim 21 is a broader chewable ER design with two discrete IR components (an uncoated ion-exchange complex IR fraction plus an uncomplexed IR fraction). The patent also includes method-of-use claims for ADHD/ADD treatment with the claimed tablet.
Below is a claim-by-claim scope map, infringement-relevant interpretation points, and the likely US patent landscape features that determine whether generics or pediatric chewable competitors face meaningful Orange Book and litigation exposure.
What does US 11,103,495 claim coverage actually require for infringement?
Core infringement product definition: a racemic methylphenidate chewable tablet that is (A) a uniform solid dispersion containing (a) a barrier-coated racemic methylphenidate–cation exchange resin complex (optionally in a matrix), and (b) immediate-release methylphenidate delivered by at least one IR component that releases methylphenidate quickly.
Independent claim 1: ER profile from barrier-coated cation-exchange complex plus at least one fast IR component
Claim 1 requires all of the following structural/functional limitations:
-
Dosage form and physical presentation
- A chewable tablet.
- “Uniform solid dispersion” structure for the drug-containing system.
-
Sustained-release fraction (component a)
- A water-insoluble, water-permeable, pH-independent barrier coating.
- The barrier coating is applied over a precoated racemic methylphenidate–cation exchange resin complex (with an optional matrix).
- Barrier coating composition requires:
- a water-insoluble barrier coating polymer and
- a plasticizer,
- barrier coating present at about 10% w/w to about 70% w/w based on the weight of the precoated complex–optional matrix.
- The barrier-coated complex provides sustained release of racemic methylphenidate.
-
Optional matrix must be specific in type
- When present, the matrix comprises:
- the racemic methylphenidate–cation exchange resin complex and
- further comprises either:
- a water-insoluble polymer/copolymer, or
- a water-soluble polymer/copolymer.
-
Immediate-release fraction (component b)
- At least one immediate release racemic methylphenidate component.
- The IR component releases racemic methylphenidate in less than about 30 minutes in an in vitro dissolution assay.
-
Quantitative split of sustained vs immediate
- About 50% w/w to about 90% w/w of the total racemic methylphenidate in the tablet is provided by the sustained-release component (a).
-
Divisibility limitation
- The chewable tablet is capable of being divided and tablet portions retain the release profile after oral dosing.
- This matters for pediatric formulations and for infringement defenses targeting split behavior.
Independent claim 21: two-component IR system (uncoated complex + uncomplexed methylphenidate)
Claim 21 also requires the same ER sustained-release “barrier-coated cation-exchange complex” framework, but changes the immediate-release package:
- Sustained-release component (a): same barrier-coated complex requirements (10% to 70% barrier coating, water-insoluble/water-permeable/pH-independent, plasticized polymer, etc.).
- Immediate-release is split into:
- (b) a first immediate-release component = immediate-release uncoated racemic methylphenidate–ion exchange resin complex, contributing ~5% to ~20% of total racemic methylphenidate.
- (c) a second immediate-release component = uncomplexed racemic methylphenidate (or salt by implication in later claims), contributing ~5% to ~20%.
- The rest of the total (implicitly 60% to 80%) is sustained via (a). Claim 22 states this explicitly.
Practical meaning
If a generic or follow-on product:
- uses enteric/pH-dependent coatings, it can fall outside the claim (claims 2/3/24).
- uses non-water-permeable or pH-dependent barrier concepts, it can fall outside.
- uses a different approach to ER generation (for example, matrix-only ER without barrier-coated ion-exchange resin), it can fall outside.
- uses a different IR scheme (for example, only complexed IR or only uncomplexed IR, or slower IR release profiles), it can fall outside.
Which claim limitations are the highest-risk “knockout” features for generics?
Highest-risk limitations are those that (i) are explicit, (ii) are difficult to “design around” while keeping therapeutic performance, and (iii) map to typical formulation shortcuts.
1) Barrier coating must be water-insoluble, water-permeable, and pH-independent
Claims 1 and 21 center the barrier coating’s physicochemical properties:
- “water-insoluble”
- “water-permeable”
- “pH-independent”
Claims 2, 3, 24 eliminate pH-dependent enteric coatings.
Design-around risk: many ER chewable concepts lean on enteric-type or pH-triggered polymers. The patent disallows pH-dependent enteric coating in multiple dependent claims.
2) Barrier coating cannot be enteric/pH-dependent
- Claim 2: extended release tablet of claim 1 has barrier-coated complex and does not comprise delayed release pH-dependent enteric coating.
- Claim 3: the tablet does not comprise a pH-dependent enteric coating.
- Claim 24: similar exclusion in claim 21 family.
Design-around risk: if a competitor uses an enteric component for “ER” behavior, it can be excluded.
3) Quantitative barrier coating wt% and plasticizer wt% ranges
Claim 1 barrier coating: ~10% to ~70% w/w (based on precoated complex–optional matrix).
- Claim 4 narrows: ~15% to ~65%.
- Claim 5/6: plasticizer 2%–50% (barrier coating basis) and narrower 2.5%–20% for claim 6.
- Claim 7: triacetin is one specific plasticizer.
Design-around risk: these ranges are formulation-specific. A product that moves barrier coating outside the claimed wt% window may avoid claim coverage, though doctrine of equivalents could still be argued in litigation.
4) Sustained fraction must be 50%–90% of racemic methylphenidate
Claim 1: ~50%–~90% w/w provided by sustained-release component (a).
Claim 22 tightens: ~60%–~80% in the claim 21 framework.
Design-around risk: shifting IR fraction upward or downward could avoid meeting the claimed split.
5) IR release must occur quickly in vitro
Claim 1 requires IR release in less than ~30 minutes.
Claim 30 later frames the IR release in less than 20 minutes (less-than-20-minute language).
Design-around risk: if dissolution is slower than the stated threshold, infringement of the “IR component releases in less than X minutes” limitation becomes harder.
6) Divisibility while retaining ER profile
Claim 1: tablet is divisible and divided portions retain release profile.
Design-around risk: if a competitor’s chewable design degrades ER behavior upon division, it may be a non-infringement angle.
What do the dependent claims add to scope and how do they affect claim charts?
Barrier polymer / coating composition (claims 15–17)
- Claim 16: barrier coating options:
- cured, water-permeable, non-ionic, pH-independent barrier coating comprising:
- polyvinylacetate,
- stabilizer,
- plasticizer, applied as aqueous dispersion; or
- ethylcellulose coating with plasticizer.
- Claim 17: example composition:
- ~70–90% w/w polyvinylacetate,
- stabilizer,
- ~2–10% w/w plasticizer.
- Claim 15: tensile strength ~150%–~400% (this is a mechanical property limitation).
Infringement implications: these dependent claims create narrower coverage but also offer additional testing hooks:
- coating tensile strength measurements,
- polymer identity,
- plasticizer type and loading.
Optional matrix composition (claims 18–19)
- Claim 18: matrix present and comprises polyvinylpyrrolidone (PVP).
- Claim 19: matrix present and comprises water-insoluble polymer/copolymer.
Infringement implications: if a competitor uses a different matrix polymer class, it may avoid these narrower dependent claims, while still potentially infringing claim 1/21 if claim 1/21 allow optional matrix broadly.
Uncomplexed IR forms and salts (claims 12–14)
- Claim 12: immediate release component comprises uncomplexed racemic methylphenidate or pharmaceutically acceptable salt.
- Claim 13: salt example is racemic methylphenidate HCl.
- Claim 14: uncomplexed immediate release component amount ~5%–35%.
Infringement implications: these are important for product designs that rely on uncomplexed methylphenidate as the fast fraction, especially if they avoid ion-exchange complex IR fractions.
Dose strengths and equivalence (claim 20)
- tablet contains equivalent of:
- 20 mg racemic methylphenidate HCl,
- 30 mg,
- or 40 mg.
Infringement implications: if a competitor never markets those strengths in the US, risk may be product-level rather than claim-level, but US litigation can still assert if manufactured for other markets or if tablets match the equivalence definition.
Method-of-use claims: what clinical and regulatory events map to them?
Claim 29
- Oral delivering claim 2 tablet to treat ADHD and/or ADD.
- Requires “clinically observable psychological and/or behavioral response … for a sustained period post-ingestion.”
This ties pharmacodynamic effect to sustained profile, but does not add a specific dissolution test threshold beyond “sustained period.”
Claim 30
- Oral delivering claim 1 tablet.
- Requires:
- (a) sustained release via barrier-coated complex and
- (b) IR provides release in less than about 20 minutes.
Infringement implications: method claims in Hatch-Waxman contexts often align with proposed labeling and the “intended use” in the ANDA. If a generic’s proposed use matches ADHD/ADD and the dissolution profile matches the IR requirement, exposure is higher.
How does US 11,103,495 compare with typical methylphenidate ER chewable architectures?
Typical methylphenidate ER alternatives:
- osmotic pump systems,
- bead technologies (ion-exchange or coated beads),
- matrix ER tablets,
- enteric-coated pH-dependent systems,
- prodrug or alternative release mechanisms.
US 11,103,495 is distinguished by:
- chewable dosage form capable of division with retained release,
- barrier-coated ion-exchange complex that is explicitly pH-independent and non-enteric,
- a specific quantitative blend of sustained vs fast-release fractions,
- a fast-release component defined by in vitro dissolution times.
This is a relatively specific formulation claim set rather than a broad “any ER chewable methylphenidate” claim.
What patents likely sit near 11,103,495 in the US landscape?
The claims indicate coverage around:
- racemic methylphenidate (base) plus resin complexes,
- barrier coating polymer/plasticizer systems,
- chewable solid dispersion and mechanical properties,
- ER/IR fraction ratios and dissolution-defined fast release,
- divisibility with maintained release profile,
- ADHD/ADD treatment methods.
In practical US patent landscapes, similar technology clusters often include:
- earlier patents on methylphenidate–resin complexes,
- later patents on coated complexes (barrier coating, ethylcellulose or PVA barrier concepts),
- composition-of-matter patents on specific coating recipes and ratios,
- formulation patents on chewable ER and divisibility behavior,
- method patents on dosing regimens with sustained behavioral response.
However, without the underlying bibliographic record (filing date, priority, assignees, patent family members) and without the USPTO/Orange Book listing data for the related approved product(s), the number and identity of adjacent US patents cannot be reliably enumerated here.
When does US 11,103,495 lose exclusivity?
This requires:
- the patent’s issuance date,
- its earliest effective filing date,
- whether it has PTA and whether any terminal disclaimers apply.
Those data points are not provided in the prompt; therefore an exclusivity/expiration timeline cannot be stated accurately.
Orange Book status, Paragraph IV risk, and generic entry scenario
These require:
- the specific FDA-approved drug product(s) that list this patent in the Orange Book,
- listed drug (RLD) identity,
- whether the patent is tied to drug substance, drug product, or method-of-use,
- whether the patent is listed with a specific expiration type (e.g., use code),
- ANDA applicant histories and any Paragraph IV filings.
No Orange Book/RLD listing is provided, so Paragraph IV and generic launch risk cannot be mapped without inventing facts.
Key Takeaways
- US 11,103,495 is a formulation-and-architecture patent for a racemic methylphenidate chewable ER tablet with a pH-independent, water-insoluble/water-permeable barrier-coated ion-exchange complex plus a defined fast IR fraction based on in vitro dissolution time.
- Independent claim 1 requires 50%–90% sustained and IR release in <30 minutes; independent claim 21 requires a two-part IR system (uncoated ion-exchange complex + uncomplexed methylphenidate), each contributing ~5%–20%.
- Dependent claims add specific coating compositions (PVA-based or ethylcellulose-based with plasticizer), plasticizer type (triacetin), mechanical strength (tensile strength), matrix polymer options (including PVP), and explicit exclusion of pH-dependent enteric coatings.
- Method claims track ADHD/ADD treatment with a sustained behavioral response and (in claim 30) an additional <20 minute dissolution-driven IR requirement.
FAQs
-
Can a formulation with an enteric coating still fall under US 11,103,495?
Claims 2, 3, and 24 explicitly exclude pH-dependent enteric/delayed-release components in the ER versions.
-
Is triacetin required to infringe?
Triacetin is only specified in dependent claim 7; infringement of independent claim 1/21 does not require triacetin.
-
How does the “<30 minutes” dissolution limitation get used in litigation?
It is an element of claim 1’s IR component definition, so claim charts typically hinge on dissolution method and test conditions matching the patent assay.
-
What design change most directly avoids claim 1/21?
Shifting the product away from a water-insoluble, water-permeable, pH-independent barrier-coated resin-complex ER mechanism, or changing the sustained vs IR fraction split outside claimed ranges.
-
Does claim scope cover only specific strengths (20/30/40 mg equivalents)?
Claim 20 recites those equivalents as a dependent limitation, but independent claim coverage is not restricted to those strengths unless the asserted claim depends on claim 20.
References
- US Patent 11,103,495 (claims text provided in the prompt).
